在博茨瓦纳的乳腺癌幸存者中,获得和利用内分泌疗法
James R Wester1, Rachel B Wagner2, Bosa Motladiile3
1Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
JCO global oncology
|December 12, 2024
概括
博茨瓦纳的乳腺癌幸存者面临着对内分泌疗法 (ET) 访问的重大障碍,包括有限的咨询和药物负担能力挑战. 改善医疗保健系统和提供者沟通对于遵守和减少复发风险至关重要.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 乳腺癌 (BC) 是全球女性癌症死亡的主要原因,撒哈拉以南非洲的发病率正在上升.
- 内分泌疗法 (ET) 显著降低了激素受体阳性 (HR +) 乳腺癌患者的复发风险一半,如果服用5-10年.
研究的目的:
- 在博茨瓦纳的乳腺癌幸存者中探索经验并确定内分泌疗法 (ET) 使用的障碍.
- 了解影响在撒哈拉以南非洲背景下坚持ET的因素.
主要方法:
- 半结构面试对19名被诊断为乳腺切除术后1-5年内患有非转移性乳腺癌的妇女进行了半结构面试.
- 主题内容分析侧重于对ET的经验,包括应该接受ET的HR+癌症妇女和报告接受ET的HR-妇女.
主要成果:
- 确定的主要障碍包括有限的提供者对ET的咨询,在公共药店处方补充的困难 (停药,政策),以及私人药店药品和运输的高成本.
- 低社会经济地位 (SEP) 与药物转换和停药有关.
- 促进补充的因素包括女性的坚持,SEP和财务支持;副作用不是停止的主要原因.
结论:
- 博茨瓦纳的乳腺癌幸存者在获得和坚持必要的内分泌治疗方面遇到多方面的障碍.
- 改善有关ET的重要性的提供者沟通以及加强医疗系统对药物可获得性和负担能力的支持是至关重要的.
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K